Siemens Healthineers AGMEX:SHL N 72 ROE % is 10.98% as of Mar. 2026, which is 11% below its 10-year median of 12.33. GuruFocus rates MEX:SHL N with a GF Score™ of 72/100 and a GF Value™ of MXN1,405.64. The stock has 5 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Siemens Healthineers AG ranks better than 78.85% on this metric.
The historical rank and industry rank for Siemens Healthineers AG's ROE % or its related term are showing as below:
MEX:SHL N'
s ROE % Range Over the Past 10 Years
Min: 7.96 Med: 12.33 Max: 47.94
Current: 11.51
During the past 11 years, Siemens Healthineers AG's highest ROE % was 47.94%. The lowest was 7.96%. And the median was 12.33%.
MEX:SHL N's ROE % is ranked better than 78.85% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs MEX:SHL N: 11.51
Siemens Healthineers AG (MEX:SHL N) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Siemens Healthineers AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siemens Healthineers AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Siemens Healthineers AG's ROE % distribution charts can be found below:
* The bar in red indicates where Siemens Healthineers AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Siemens Healthineers AG (MEX:SHL N) has a ROE % of 10.98% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Siemens Healthineers AG and its competitors. This is 11% below median its historical median of 12.33. Over the past decade, Siemens Healthineers AG's ROE % has ranged from 7.96 to 47.94. According to the industry distribution chart, Siemens Healthineers AG ranks #169 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 21.2%.
Is Siemens Healthineers AG's ROE % too high?
Siemens Healthineers AG's current ROE % of 10.98% is 11% below median its 10-year median of 12.33. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 47.94. The Medical Devices & Instruments industry median ROE % is 2.42. Siemens Healthineers AG's value of 10.98% is 353.7% above this industry median. Based on the distribution chart, Siemens Healthineers AG ranks #169 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Siemens Healthineers AG has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Siemens Healthineers AG's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Siemens Healthineers AG ranks #169 out of 799 companies for ROE %. This places Siemens Healthineers AG in the top 21% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Siemens Healthineers AG's value of 10.98% is 353.7% above this benchmark. Historically, Siemens Healthineers AG's own ROE % has ranged from 7.96 to 47.94 over the past decade. While the company's 10-year median is 12.33 vs. the industry median of 2.42, Siemens Healthineers AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siemens Healthineers AG's current ROE % of 10.98% is 353.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Siemens Healthineers AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siemens Healthineers AG's current ROE % is 10.98%, which is 11% below median its own 10-year median of 12.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siemens Healthineers AG stock overvalued right now?
Siemens Healthineers AG (MEX:SHL N) has a current ROE % of 10.98%. The stock's GF Value™ is MXN1,405.64, compared to a current price of MXN918.93 — trading 34.6% below its estimated fair value. The current ROE % is 10.98%, which is 11% below median its 10-year median of 12.33 and 353.7% above the Medical Devices & Instruments industry median of 2.42. Siemens Healthineers AG's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Siemens Healthineers AG (MEX:SHL N), the current ROE % is 10.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siemens Healthineers AG (MEX:SHL N) Overvalued in 2026?
Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued.
The current stock price of MXN918.93 is trading 34.6% below its estimated GF Value™ of MXN1,405.64.
Key valuation signals for MEX:SHL N:
ROE %: 10.98% (11% below median its 10-year median of 12.33)
GF Value™: MXN1,405.64 vs. price of MXN918.93 (34.6% below fair value)
Industry Position: 353.7% above the Medical Devices & Instruments median (#169 of 799)
No single metric tells the full story. See the MEX:SHL N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
72GF Score
Get the complete analysis for MEX:SHL N
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SHL N has been successfully added to your 
